UCB's $1.5bn generics unit sale falls through
This article was originally published in Scrip
Executive Summary
UCB's sale of its generics business unit, worth $1.525bn, has fallen through as a result of "an unexpected conflict" in timing with buyers Advent International and Avista Capital Partners.